GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Galectin Therapeutics Inc (FRA:PHPN) » Definitions » YoY EPS Growth

Galectin Therapeutics (FRA:PHPN) YoY EPS Growth : 13.53% (As of Dec. 2023)


View and export this data going back to 2007. Start your Free Trial

What is Galectin Therapeutics YoY EPS Growth?

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months. Galectin Therapeutics's YoY EPS Growth for the quarter that ended in Dec. 2023 was 13.53%.

Galectin Therapeutics's Earnings per Share (Diluted) for the three months ended in Dec. 2023 was €-0.15.

Galectin Therapeutics YoY EPS Growth Historical Data

The historical data trend for Galectin Therapeutics's YoY EPS Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Galectin Therapeutics YoY EPS Growth Chart

Galectin Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
YoY EPS Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only -5.09 3.99 -36.50 -33.48 -10.59

Galectin Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
YoY EPS Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -60.38 -14.94 8.61 -59.57 13.53

Galectin Therapeutics YoY EPS Growth Calculation

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months.

Galectin Therapeutics's YoY EPS Growth for the fiscal year that ended in Dec. 2023 is calculated as:

YoY EPS Growth (A: Dec. 2023 )
=(Earnings per Share (Diluted) (A: Dec. 2023 )-Earnings per Share (Diluted) (A: Dec. 2022 ))/ | Earnings per Share (Diluted) (A: Dec. 2022 ) |
=(-0.679--0.614)/ | -0.614 |
=-10.59 %

Galectin Therapeutics's YoY EPS Growth for the quarter that ended in Dec. 2023 is calculated as:

YoY EPS Growth (Q: Dec. 2023 )
=(Earnings per Share (Diluted) (Q: Dec. 2023 )-Earnings per Share (Diluted) (Q: Dec. 2022 )) / | Earnings per Share (Diluted) (Q: Dec. 2022 )) |
=(-0.147--0.17)/ | -0.17 |
=13.53 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Galectin Therapeutics YoY EPS Growth Related Terms

Thank you for viewing the detailed overview of Galectin Therapeutics's YoY EPS Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Galectin Therapeutics (FRA:PHPN) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Galectin Therapeutics Inc (FRA:PHPN) » Definitions » YoY EPS Growth
Comparable Companies
DSGN MACK LCTX INMB QURE TSVT GTHX OVID RENB PSTX OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB XBRU:ARGX BNTX
Traded in Other Exchanges
GALT:USA
Address
4960 Peachtree Industrial Boulevard, Suite 240, Norcross, GA, USA, 30071
Website
https://www.galectintherapeutics.com
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its lead galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.

Galectin Therapeutics (FRA:PHPN) Headlines

No Headlines